Compare TWI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWI | TECX |
|---|---|---|
| Founded | 1890 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.4M | 549.5M |
| IPO Year | 1997 | N/A |
| Metric | TWI | TECX |
|---|---|---|
| Price | $7.88 | $31.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 432.2K | 114.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.69 | N/A |
| Revenue Next Year | $4.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $14.39 |
| 52 Week High | $11.70 | $35.99 |
| Indicator | TWI | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 59.40 |
| Support Level | $7.17 | $27.31 |
| Resistance Level | $8.26 | $31.39 |
| Average True Range (ATR) | 0.30 | 1.80 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 76.02 | 80.25 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. It designs and manufactures products for OEMs and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. The company operates through three segments, namely Agricultural, Earthmoving/Construction, and Consumer. It derives the majority of revenue from the Agricultural segment which manufactures various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment. Geographically, the company generates the maximum revenue from North America, followed by Europe / CIS, Latin America, and Asia and other regions.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.